N.H., (March 14, 2019) – iCAD,
(NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today reported
strong adoption of its latest deep-learning, cancer detection software solution
for digital breast tomosynthesis (DBT), ProFound AI™. The powerful solution
built on artificial intelligence (AI) delivers critical benefits to
radiologists, their facilities and patients in identifying cancer earlier.


“ProFound AI for DBT is like having another radiologist
right there in the reading room with you,” said Randy Hicks, M.D., MBA, radiologist, co-owner and CEO at Regional Medical
Imaging. “It’s software you can trust to help diagnose cancers and improve
workflow, keeping physicians on track and enabling them to read cases more


Since the product was launched in the United States in
December 2018, ProFound AI has been adopted by a significant number of high-profile
hospitals and imaging centers in all major geographic areas of the country,
demonstrating the strong need for such revolutionary


“We are very
pleased with the preliminary success and strong adoption of
ProFound AI among some of the top luminary
sites in the U.S.,” said Stacey Stevens, executive
vice president and chief strategy and commercial officer at iCAD. “This strong
initial adoption of ProFound AI now allows us to create powerful reference
sites, customer testimonials and educational events that will further
accelerate growth of this unprecedented solution.   As the
only FDA cleared provider of AI technology for digital breast tomosynthesis, we
look forward to driving continued adoption, ultimately transforming breast
cancer detection and improving patient lives.”


AI is a high-performance, deep-learning, cancer detection and workflow solution
for DBT delivering critical benefits to radiologists, their facilities, and
their patients
through the improvement of cancer detection rates by an
average of 8 percent and decreasing unnecessary patient recall rates by an
average of 7 percent. The new technology has been trained to detect malignant
soft-tissue densities and calcifications. It also provides radiologists with
scoring information representing the likelihood that a detection or case is
malignant based on the large dataset of clinical images used to train the


“Following our
recent implementation of ProFound AI from iCAD, we have already recognized the
value and benefits it is providing to us in reading our DBT studies. Our
radiologists appreciate this compelling technology and the high sensitivity and
specificity it delivers in identifying lesion markings. It is imperative
for us to continue providing the community with the best technology available to
detect breast cancer, and our use of ProFound AI is indicative of this,” said
Harold Tanenbaum, M.D., radiologist, medical director Marine Park Radiology, NY.


In addition to
improving clinical performance related to breast cancer detection and false
positive rates, study results showed that ProFound AI can reduce radiologists’
reading time by more than 50 percent on average. An increase in reading time
has been a significant challenge for radiologists when moving from 2D to 3D


are proud to be using ProFound AI for DBT to assist our radiology team in
providing improved quality patient care. Timing is critical for patients with
hidden breast cancers, and the combination of 3D mammography and iCAD’s ProFound
AI software could be life saving,” said John Ervin, imaging director for Hunt
Regional Healthcare.


ProFound AI is currently available for use with leading DBT
systems in the U.S., Canada and Europe.
For more information about the solution and its benefits, visit


About iCAD, Inc.


Headquartered in Nashua, NH, iCAD is a global
medical technology leader providing innovative cancer detection and therapy
solutions. For more information, visit


“Safe Harbor” Statement under the Private
Securities Litigation Reform Act of 1995


Certain statements contained in this News Release
constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
involve a number of known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the Company
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors include,
but are not limited to the Company’s ability to defend itself in litigation
matters, to achieve business and strategic objectives, the risks of uncertainty
of patent protection, the impact of supply and manufacturing constraints or
difficulties, uncertainty of future sales levels, protection of patents and
other proprietary rights, product market acceptance, possible technological
obsolescence of products, increased competition, litigation and/or government
regulation, changes in Medicare or other reimbursement policies, risks relating
to our existing and future debt obligations, competitive factors, the effects
of a decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”,
“consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”,
“seek”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, including the 10-K for the year ended December 31, 2018,
available on the Investors section of our website at and
on the SEC’s website at




Media Inquiries:

ARPR, on behalf of iCAD, Inc.

Paul Barren, (855) 300-8209


Investor Relations:

LifeSci Advisors

Jeremy Feffer, (212) 915-2568